Type 2 diabetes is a progressive condition in which the body becomes resistant to the normal effects of insulin and/or gradually loses the capacity to produce enough insulin in the pancreas. We do not know what causes type 2 diabetes. Type 2 diabetes is associated with modifiable lifestyle risk factors. Type 2 diabetes also has strong genetic and family related risk factors.
The dramatic increase in the prevalence, progressive nature and diagnosis of type 2 diabetes is the main driver of this rapid growth rate. The rise in disease-related comorbidities has also fuelled a more aggressive approach to treatment, including the use of multiple-drug therapies.
The Americas dominated the global type 1 diabetes drug market and accounted for close to 50% of the global type 1 diabetes market size. The US was the largest revenue contributor to the diabetes drug market in this region because of the growing prevalence of the disease and rise in obesity. The accessibility to therapies by reimbursement programs is further expected to drive the growth of the diabetes drug market size in the Americas.
In 2019, the market size of Type 2 Diabetes is xx million US$ and it will reach xx million US$ in 2025, growing at a CAGR of xx% from 2019; while in China, the market size is valued at xx million US$ and will increase to xx million US$ in 2025, with a CAGR of xx% during forecast period.
In this report, 2018 has been considered as the base year and 2019 to 2025 as the forecast period to estimate the market size for Type 2 Diabetes.
This report studies the global market size of Type 2 Diabetes, especially focuses on the key regions like United States, European Union, China, and other regions (Japan, Korea, India and Southeast Asia).
This study presents the Type 2 Diabetes sales volume, revenue, market share and growth rate for each key company, and also covers the breakdown data (sales, revenue and market share) by regions, type and applications. history breakdown data from 2014 to 2019, and forecast to 2025.
For top companies in United States, European Union and China, this report investigates and analyzes the production, value, price, market share and growth rate for the top manufacturers, key data from 2014 to 2019.
In global market, the following companies are covered:
Novo Nordisk
Sanofi
Merck
Eli Lily
AstraZeneca
Astellas Pharma
Daiichi Sankyo
Biocon
Boehringer Ingelheim
Market Segment by Product Type
Insulins
DPP-4 Inhibitors
GLP-1 Receptor Agonists
SGLT-2 Inhibitors
Market Segment by Application
Drugstore
Hospital
Others
Key Regions split in this report: breakdown data for each region.
United States
China
European Union
Rest of World (Japan, Korea, India and Southeast Asia)
The study objectives are:
To analyze and research the Type 2 Diabetes status and future forecast in United States, European Union and China, involving sales, value (revenue), growth rate (CAGR), market share, historical and forecast.
To present the key Type 2 Diabetes manufacturers, presenting the sales, revenue, market share, and recent development for key players.
To split the breakdown data by regions, type, companies and applications
To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints and risks.
To identify significant trends, drivers, influence factors in global and regions
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market
In this study, the years considered to estimate the market size of Type 2 Diabetes are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
The dramatic increase in the prevalence, progressive nature and diagnosis of type 2 diabetes is the main driver of this rapid growth rate. The rise in disease-related comorbidities has also fuelled a more aggressive approach to treatment, including the use of multiple-drug therapies.
The Americas dominated the global type 1 diabetes drug market and accounted for close to 50% of the global type 1 diabetes market size. The US was the largest revenue contributor to the diabetes drug market in this region because of the growing prevalence of the disease and rise in obesity. The accessibility to therapies by reimbursement programs is further expected to drive the growth of the diabetes drug market size in the Americas.
In 2019, the market size of Type 2 Diabetes is xx million US$ and it will reach xx million US$ in 2025, growing at a CAGR of xx% from 2019; while in China, the market size is valued at xx million US$ and will increase to xx million US$ in 2025, with a CAGR of xx% during forecast period.
In this report, 2018 has been considered as the base year and 2019 to 2025 as the forecast period to estimate the market size for Type 2 Diabetes.
This report studies the global market size of Type 2 Diabetes, especially focuses on the key regions like United States, European Union, China, and other regions (Japan, Korea, India and Southeast Asia).
This study presents the Type 2 Diabetes sales volume, revenue, market share and growth rate for each key company, and also covers the breakdown data (sales, revenue and market share) by regions, type and applications. history breakdown data from 2014 to 2019, and forecast to 2025.
For top companies in United States, European Union and China, this report investigates and analyzes the production, value, price, market share and growth rate for the top manufacturers, key data from 2014 to 2019.
In global market, the following companies are covered:
Novo Nordisk
Sanofi
Merck
Eli Lily
AstraZeneca
Astellas Pharma
Daiichi Sankyo
Biocon
Boehringer Ingelheim
Market Segment by Product Type
Insulins
DPP-4 Inhibitors
GLP-1 Receptor Agonists
SGLT-2 Inhibitors
Market Segment by Application
Drugstore
Hospital
Others
Key Regions split in this report: breakdown data for each region.
United States
China
European Union
Rest of World (Japan, Korea, India and Southeast Asia)
The study objectives are:
To analyze and research the Type 2 Diabetes status and future forecast in United States, European Union and China, involving sales, value (revenue), growth rate (CAGR), market share, historical and forecast.
To present the key Type 2 Diabetes manufacturers, presenting the sales, revenue, market share, and recent development for key players.
To split the breakdown data by regions, type, companies and applications
To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints and risks.
To identify significant trends, drivers, influence factors in global and regions
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market
In this study, the years considered to estimate the market size of Type 2 Diabetes are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
Table of Contents
1 Report Overview
1.1 Study Scope
1.2 Major Manufacturers Covered in This Report
1.3 Market Segment by Type
1.3.1 Global Type 2 Diabetes Market Size Growth Rate by Type (2019-2025)
1.3.2 Insulins
1.3.3 DPP-4 Inhibitors
1.3.4 GLP-1 Receptor Agonists
1.3.5 SGLT-2 Inhibitors
1.4 Market Segment by Application
1.4.1 Global Type 2 Diabetes Market Share by Application (2019-2025)
1.4.2 Drugstore
1.4.3 Hospital
1.4.4 Others
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Type 2 Diabetes Market Size
2.1.1 Global Type 2 Diabetes Revenue 2014-2025
2.1.2 Global Type 2 Diabetes Sales 2014-2025
2.2 Type 2 Diabetes Growth Rate by Regions
2.2.1 Global Type 2 Diabetes Sales by Regions 2014-2019
2.2.2 Global Type 2 Diabetes Revenue by Regions 2014-2019
2.3 Industry Trends
2.3.1 Market Top Trends
2.3.2 Market Drivers
3 Market Share by Manufacturers
3.1 Type 2 Diabetes Sales by Manufacturers
3.1.1 Type 2 Diabetes Sales by Manufacturers 2014-2019
3.1.2 Type 2 Diabetes Sales Market Share by Manufacturers 2014-2019
3.2 Revenue by Manufacturers
3.2.1 Type 2 Diabetes Revenue by Manufacturers (2014-2019)
3.2.2 Type 2 Diabetes Revenue Share by Manufacturers (2014-2019)
3.2.3 Global Type 2 Diabetes Market Concentration Ratio (CR5 and HHI)
3.3 Type 2 Diabetes Price by Manufacturers
3.4 Key Manufacturers Type 2 Diabetes Plants/Factories Distribution and Area Served
3.5 Date of Key Manufacturers Enter into Type 2 Diabetes Market
3.6 Key Manufacturers Type 2 Diabetes Product Offered
3.7 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Sales and Revenue for Each Type
4.1.1 Insulins Sales and Revenue (2014-2019)
4.1.2 DPP-4 Inhibitors Sales and Revenue (2014-2019)
4.1.3 GLP-1 Receptor Agonists Sales and Revenue (2014-2019)
4.1.4 SGLT-2 Inhibitors Sales and Revenue (2014-2019)
4.2 Global Type 2 Diabetes Sales Market Share by Type
4.3 Global Type 2 Diabetes Revenue Market Share by Type
4.4 Type 2 Diabetes Price by Type
5 Market Size by Application
5.1 Overview
5.2 Global Type 2 Diabetes Sales by Application
6 United States
6.1 United States Type 2 Diabetes Breakdown Data by Company
6.2 United States Type 2 Diabetes Breakdown Data by Type
6.3 United States Type 2 Diabetes Breakdown Data by Application
7 European Union
7.1 European Union Type 2 Diabetes Breakdown Data by Company
7.2 European Union Type 2 Diabetes Breakdown Data by Type
7.3 European Union Type 2 Diabetes Breakdown Data by Application
8 China
8.1 China Type 2 Diabetes Breakdown Data by Company
8.2 China Type 2 Diabetes Breakdown Data by Type
8.3 China Type 2 Diabetes Breakdown Data by Application
9 Rest of World
9.1 Rest of World Type 2 Diabetes Breakdown Data by Company
9.2 Rest of World Type 2 Diabetes Breakdown Data by Type
9.3 Rest of World Type 2 Diabetes Breakdown Data by Application
9.4 Rest of World Type 2 Diabetes Breakdown Data by Countries
9.4.1 Rest of World Type 2 Diabetes Sales by Countries
9.4.2 Rest of World Type 2 Diabetes Revenue by Countries
9.4.3 Japan
9.4.4 Korea
9.4.5 India
9.4.6 Southeast Asia
10 Company Profiles
10.1 Novo Nordisk
10.1.1 Novo Nordisk Company Details
10.1.2 Company Description and Business Overview
10.1.3 Sales, Revenue and Market Share of Type 2 Diabetes
10.1.4 Type 2 Diabetes Product Introduction
10.1.5 Novo Nordisk Recent Development
10.2 Sanofi
10.2.1 Sanofi Company Details
10.2.2 Company Description and Business Overview
10.2.3 Sales, Revenue and Market Share of Type 2 Diabetes
10.2.4 Type 2 Diabetes Product Introduction
10.2.5 Sanofi Recent Development
10.3 Merck
10.3.1 Merck Company Details
10.3.2 Company Description and Business Overview
10.3.3 Sales, Revenue and Market Share of Type 2 Diabetes
10.3.4 Type 2 Diabetes Product Introduction
10.3.5 Merck Recent Development
10.4 Eli Lily
10.4.1 Eli Lily Company Details
10.4.2 Company Description and Business Overview
10.4.3 Sales, Revenue and Market Share of Type 2 Diabetes
10.4.4 Type 2 Diabetes Product Introduction
10.4.5 Eli Lily Recent Development
10.5 AstraZeneca
10.5.1 AstraZeneca Company Details
10.5.2 Company Description and Business Overview
10.5.3 Sales, Revenue and Market Share of Type 2 Diabetes
10.5.4 Type 2 Diabetes Product Introduction
10.5.5 AstraZeneca Recent Development
10.6 Astellas Pharma
10.6.1 Astellas Pharma Company Details
10.6.2 Company Description and Business Overview
10.6.3 Sales, Revenue and Market Share of Type 2 Diabetes
10.6.4 Type 2 Diabetes Product Introduction
10.6.5 Astellas Pharma Recent Development
10.7 Daiichi Sankyo
10.7.1 Daiichi Sankyo Company Details
10.7.2 Company Description and Business Overview
10.7.3 Sales, Revenue and Market Share of Type 2 Diabetes
10.7.4 Type 2 Diabetes Product Introduction
10.7.5 Daiichi Sankyo Recent Development
10.8 Biocon
10.8.1 Biocon Company Details
10.8.2 Company Description and Business Overview
10.8.3 Sales, Revenue and Market Share of Type 2 Diabetes
10.8.4 Type 2 Diabetes Product Introduction
10.8.5 Biocon Recent Development
10.9 Boehringer Ingelheim
10.9.1 Boehringer Ingelheim Company Details
10.9.2 Company Description and Business Overview
10.9.3 Sales, Revenue and Market Share of Type 2 Diabetes
10.9.4 Type 2 Diabetes Product Introduction
10.9.5 Boehringer Ingelheim Recent Development
11 Value Chain and Sales Channels Analysis
11.1 Value Chain Analysis
11.2 Sales Channels Analysis
11.2.1 Type 2 Diabetes Sales Channels
11.2.2 Type 2 Diabetes Distributors
11.3 Type 2 Diabetes Customers
12 Market Forecast
12.1 Global Type 2 Diabetes Sales and Revenue Forecast 2019-2025
12.2 Global Type 2 Diabetes Sales Forecast by Type
12.3 Global Type 2 Diabetes Sales Forecast by Application
12.4 Type 2 Diabetes Forecast by Regions
12.4.1 Global Type 2 Diabetes Sales Forecast by Regions 2019-2025
12.4.2 Global Type 2 Diabetes Revenue Forecast by Regions 2019-2025
12.5 United States Market Forecast
12.6 European Union Market Forecast
12.7 China Market Forecast
12.8 Rest of World
12.8.1 Japan
12.8.2 Korea
12.8.3 India
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.1.1 Research Programs/Design
14.1.1.2 Market Size Estimation
14.1.1.3 Market Breakdown and Data Triangulation
14.1.2 Data Source
14.1.2.1 Secondary Sources
14.1.2.2 Primary Sources
14.2 Author Details
14.3 Disclaimer
1 Report Overview
1.1 Study Scope
1.2 Major Manufacturers Covered in This Report
1.3 Market Segment by Type
1.3.1 Global Type 2 Diabetes Market Size Growth Rate by Type (2019-2025)
1.3.2 Insulins
1.3.3 DPP-4 Inhibitors
1.3.4 GLP-1 Receptor Agonists
1.3.5 SGLT-2 Inhibitors
1.4 Market Segment by Application
1.4.1 Global Type 2 Diabetes Market Share by Application (2019-2025)
1.4.2 Drugstore
1.4.3 Hospital
1.4.4 Others
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Type 2 Diabetes Market Size
2.1.1 Global Type 2 Diabetes Revenue 2014-2025
2.1.2 Global Type 2 Diabetes Sales 2014-2025
2.2 Type 2 Diabetes Growth Rate by Regions
2.2.1 Global Type 2 Diabetes Sales by Regions 2014-2019
2.2.2 Global Type 2 Diabetes Revenue by Regions 2014-2019
2.3 Industry Trends
2.3.1 Market Top Trends
2.3.2 Market Drivers
3 Market Share by Manufacturers
3.1 Type 2 Diabetes Sales by Manufacturers
3.1.1 Type 2 Diabetes Sales by Manufacturers 2014-2019
3.1.2 Type 2 Diabetes Sales Market Share by Manufacturers 2014-2019
3.2 Revenue by Manufacturers
3.2.1 Type 2 Diabetes Revenue by Manufacturers (2014-2019)
3.2.2 Type 2 Diabetes Revenue Share by Manufacturers (2014-2019)
3.2.3 Global Type 2 Diabetes Market Concentration Ratio (CR5 and HHI)
3.3 Type 2 Diabetes Price by Manufacturers
3.4 Key Manufacturers Type 2 Diabetes Plants/Factories Distribution and Area Served
3.5 Date of Key Manufacturers Enter into Type 2 Diabetes Market
3.6 Key Manufacturers Type 2 Diabetes Product Offered
3.7 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Sales and Revenue for Each Type
4.1.1 Insulins Sales and Revenue (2014-2019)
4.1.2 DPP-4 Inhibitors Sales and Revenue (2014-2019)
4.1.3 GLP-1 Receptor Agonists Sales and Revenue (2014-2019)
4.1.4 SGLT-2 Inhibitors Sales and Revenue (2014-2019)
4.2 Global Type 2 Diabetes Sales Market Share by Type
4.3 Global Type 2 Diabetes Revenue Market Share by Type
4.4 Type 2 Diabetes Price by Type
5 Market Size by Application
5.1 Overview
5.2 Global Type 2 Diabetes Sales by Application
6 United States
6.1 United States Type 2 Diabetes Breakdown Data by Company
6.2 United States Type 2 Diabetes Breakdown Data by Type
6.3 United States Type 2 Diabetes Breakdown Data by Application
7 European Union
7.1 European Union Type 2 Diabetes Breakdown Data by Company
7.2 European Union Type 2 Diabetes Breakdown Data by Type
7.3 European Union Type 2 Diabetes Breakdown Data by Application
8 China
8.1 China Type 2 Diabetes Breakdown Data by Company
8.2 China Type 2 Diabetes Breakdown Data by Type
8.3 China Type 2 Diabetes Breakdown Data by Application
9 Rest of World
9.1 Rest of World Type 2 Diabetes Breakdown Data by Company
9.2 Rest of World Type 2 Diabetes Breakdown Data by Type
9.3 Rest of World Type 2 Diabetes Breakdown Data by Application
9.4 Rest of World Type 2 Diabetes Breakdown Data by Countries
9.4.1 Rest of World Type 2 Diabetes Sales by Countries
9.4.2 Rest of World Type 2 Diabetes Revenue by Countries
9.4.3 Japan
9.4.4 Korea
9.4.5 India
9.4.6 Southeast Asia
10 Company Profiles
10.1 Novo Nordisk
10.1.1 Novo Nordisk Company Details
10.1.2 Company Description and Business Overview
10.1.3 Sales, Revenue and Market Share of Type 2 Diabetes
10.1.4 Type 2 Diabetes Product Introduction
10.1.5 Novo Nordisk Recent Development
10.2 Sanofi
10.2.1 Sanofi Company Details
10.2.2 Company Description and Business Overview
10.2.3 Sales, Revenue and Market Share of Type 2 Diabetes
10.2.4 Type 2 Diabetes Product Introduction
10.2.5 Sanofi Recent Development
10.3 Merck
10.3.1 Merck Company Details
10.3.2 Company Description and Business Overview
10.3.3 Sales, Revenue and Market Share of Type 2 Diabetes
10.3.4 Type 2 Diabetes Product Introduction
10.3.5 Merck Recent Development
10.4 Eli Lily
10.4.1 Eli Lily Company Details
10.4.2 Company Description and Business Overview
10.4.3 Sales, Revenue and Market Share of Type 2 Diabetes
10.4.4 Type 2 Diabetes Product Introduction
10.4.5 Eli Lily Recent Development
10.5 AstraZeneca
10.5.1 AstraZeneca Company Details
10.5.2 Company Description and Business Overview
10.5.3 Sales, Revenue and Market Share of Type 2 Diabetes
10.5.4 Type 2 Diabetes Product Introduction
10.5.5 AstraZeneca Recent Development
10.6 Astellas Pharma
10.6.1 Astellas Pharma Company Details
10.6.2 Company Description and Business Overview
10.6.3 Sales, Revenue and Market Share of Type 2 Diabetes
10.6.4 Type 2 Diabetes Product Introduction
10.6.5 Astellas Pharma Recent Development
10.7 Daiichi Sankyo
10.7.1 Daiichi Sankyo Company Details
10.7.2 Company Description and Business Overview
10.7.3 Sales, Revenue and Market Share of Type 2 Diabetes
10.7.4 Type 2 Diabetes Product Introduction
10.7.5 Daiichi Sankyo Recent Development
10.8 Biocon
10.8.1 Biocon Company Details
10.8.2 Company Description and Business Overview
10.8.3 Sales, Revenue and Market Share of Type 2 Diabetes
10.8.4 Type 2 Diabetes Product Introduction
10.8.5 Biocon Recent Development
10.9 Boehringer Ingelheim
10.9.1 Boehringer Ingelheim Company Details
10.9.2 Company Description and Business Overview
10.9.3 Sales, Revenue and Market Share of Type 2 Diabetes
10.9.4 Type 2 Diabetes Product Introduction
10.9.5 Boehringer Ingelheim Recent Development
11 Value Chain and Sales Channels Analysis
11.1 Value Chain Analysis
11.2 Sales Channels Analysis
11.2.1 Type 2 Diabetes Sales Channels
11.2.2 Type 2 Diabetes Distributors
11.3 Type 2 Diabetes Customers
12 Market Forecast
12.1 Global Type 2 Diabetes Sales and Revenue Forecast 2019-2025
12.2 Global Type 2 Diabetes Sales Forecast by Type
12.3 Global Type 2 Diabetes Sales Forecast by Application
12.4 Type 2 Diabetes Forecast by Regions
12.4.1 Global Type 2 Diabetes Sales Forecast by Regions 2019-2025
12.4.2 Global Type 2 Diabetes Revenue Forecast by Regions 2019-2025
12.5 United States Market Forecast
12.6 European Union Market Forecast
12.7 China Market Forecast
12.8 Rest of World
12.8.1 Japan
12.8.2 Korea
12.8.3 India
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.1.1 Research Programs/Design
14.1.1.2 Market Size Estimation
14.1.1.3 Market Breakdown and Data Triangulation
14.1.2 Data Source
14.1.2.1 Secondary Sources
14.1.2.2 Primary Sources
14.2 Author Details
14.3 Disclaimer
